Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 + Imatinib in CML with Persistent Molecular Disease
NCT01188889Phase 2Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Sep 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in chronic myeloid leukemia (CML), sponsored by University of Michigan Rogel Cancer Center. Planned start Sep 2013; status: withdrawn.
02
Drugs
everolimus
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01188889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01188889.